ERYTHROMYCIN

Post-LOE

erythromycin

ANDAOPHTHALMICOINTMENT
Approved
Jul 1996
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
9

Mechanism of Action

CLINICAL PHARMACOLOGY: Microbiology: Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical infections: Streptococcus pyogenes (group A β-hemolytic) Alpha-hemolytic streptococci…

Pharmacologic Class:

Macrolide

Clinical Trials (5)

NCT06948747Phase 1Completed

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

Started May 2025
49 enrolled
Healthy Participants
NCT06917872Phase 1Completed

A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood

Started Apr 2025
20 enrolled
Healthy
NCT05797753Phase 1Completed

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

Started Feb 2022
16 enrolled
Amyotrophic Lateral SclerosisHealthy Volunteer
NCT03480243Phase 1Completed

Study to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil

Started Mar 2018
28 enrolled
Pharmacokinetics
NCT01478256Phase 4Completed

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis

Started Aug 2011
30 enrolled
Blepharitis